Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with ¹⁸F-NaF PET/CT / 대한핵의학회잡지

ABSTRACT

PURPOSE@#To determine the utility of ¹⁸F-sodium fluoride positron emission tomography-computed tomography (¹⁸F-NaF PET/CT) in the imaging assessment of therapy response in men with osseous-only metastatic prostate cancer.@*METHODS@#In this Institutional Review Board-approved single institution retrospective investigation, we evaluated 21 ¹⁸F-NaF PET/CTscans performed in 14 patients with osseous metastatic disease from prostate cancer and no evidence of locally recurrent or soft-tissue metastatic disease who received chemohormonal therapy. Imaging-based qualitative and semi-quantitative parameters were defined and compared with changes in serum PSA level.@*RESULTS@#Qualitative and semi-quantitative image-based assessments demonstrated > 80% concordance with good correlation (SUV(max) κ = 0.71, SUVavg κ = 0.62, SUVsum κ = 0.62). Moderate correlation (κ = 0.43) was found between SUV(max) and PSA-based treatment response assessments. There was no statistically significant correlation between PSA-based disease progression and semi-quantitative parameters. Qualitative imaging assessment was moderately correlated (κ = 0.52) with PSA in distinguishing responders and non-responders.@*CONCLUSION@#¹⁸F-NaF PET/CT is complementary to biochemical monitoring in patients with bone-only metastases from prostate cancer which can be helpful in subsequent treatment management decisions.